Trial Watch-Oncolytic viruses and cancer therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323642" target="_blank" >RIV/00064203:_____/16:10323642 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/16:10323642
Result on the web
<a href="http://dx.doi.org/10.1080/2162402X.2015.1117740" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1117740</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2015.1117740" target="_blank" >10.1080/2162402X.2015.1117740</a>

Result language
angličtina
Original language name
Trial Watch-Oncolytic viruses and cancer therapy
Original language description
Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)